342 related articles for article (PubMed ID: 26528286)
41. TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.
Hossain DM; Pal SK; Moreira D; Duttagupta P; Zhang Q; Won H; Jones J; D'Apuzzo M; Forman S; Kortylewski M
Clin Cancer Res; 2015 Aug; 21(16):3771-82. PubMed ID: 25967142
[TBL] [Abstract][Full Text] [Related]
42. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
43. Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells.
Bianchi G; Borgonovo G; Pistoia V; Raffaghello L
Histol Histopathol; 2011 Jul; 26(7):941-51. PubMed ID: 21630223
[TBL] [Abstract][Full Text] [Related]
44. Blockade of Myd88 signaling induces antitumor effects by skewing the immunosuppressive function of myeloid-derived suppressor cells.
Hong EH; Chang SY; Lee BR; Kim YS; Lee JM; Kang CY; Kweon MN; Ko HJ
Int J Cancer; 2013 Jun; 132(12):2839-48. PubMed ID: 23184679
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic Values of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma: Facts and Hopes.
Wang Y; Zhang T; Sun M; Ji X; Xie M; Huang W; Xia L
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680276
[TBL] [Abstract][Full Text] [Related]
46. Metabolic and functional reprogramming of myeloid-derived suppressor cells and their therapeutic control in glioblastoma.
Won WJ; Deshane JS; Leavenworth JW; Oliva CR; Griguer CE
Cell Stress; 2019 Jan; 3(2):47-65. PubMed ID: 31225500
[TBL] [Abstract][Full Text] [Related]
47. Targeting myeloid-derived suppressor cells for cancer therapy.
Tang H; Li H; Sun Z
Cancer Biol Med; 2021 Aug; 18(4):992-1009. PubMed ID: 34403220
[TBL] [Abstract][Full Text] [Related]
48. Highlights on mechanisms of drugs targeting MDSCs: providing a novel perspective on cancer treatment.
Pan W; Sun Q; Wang Y; Wang J; Cao S; Ren X
Tumour Biol; 2015 May; 36(5):3159-69. PubMed ID: 25828146
[TBL] [Abstract][Full Text] [Related]
49. Myeloid-Derived Suppressor Cells: A Multifaceted Accomplice in Tumor Progression.
Cheng JN; Yuan YX; Zhu B; Jia Q
Front Cell Dev Biol; 2021; 9():740827. PubMed ID: 35004667
[TBL] [Abstract][Full Text] [Related]
50. Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves.
Sevko A; Umansky V
J Cancer; 2013; 4(1):3-11. PubMed ID: 23386900
[TBL] [Abstract][Full Text] [Related]
51. Myeloid-Derived Suppressor Cells as Key Players and Promising Therapy Targets in Prostate Cancer.
Siemińska I; Baran J
Front Oncol; 2022; 12():862416. PubMed ID: 35860573
[TBL] [Abstract][Full Text] [Related]
52. Chemotherapy-induced myeloid suppressor cells and antitumor immunity: The Janus face of chemotherapy in immunomodulation.
Ding ZC; Munn DH; Zhou G
Oncoimmunology; 2014; 3(8):e954471. PubMed ID: 25610747
[TBL] [Abstract][Full Text] [Related]
53. Application of Anti-Inflammatory Agents in Prostate Cancer.
Hatano K; Fujita K; Nonomura N
J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32824865
[TBL] [Abstract][Full Text] [Related]
54. Targeting MDSCs enhance therapeutic vaccination responses against lung cancer.
Srivastava MK; Dubinett S; Sharma S
Oncoimmunology; 2012 Dec; 1(9):1650-1651. PubMed ID: 23264925
[TBL] [Abstract][Full Text] [Related]
55. Cancer as an immune-mediated disease.
Shurin MR
Immunotargets Ther; 2012; 1():1-6. PubMed ID: 27471681
[TBL] [Abstract][Full Text] [Related]
56. Myeloid-derived suppressor cells in ovarian cancer: friend or foe?
Walankiewicz M; Grywalska E; Polak G; Kotarski J; Siwicka-Gieroba DJ; Roliński J
Cent Eur J Immunol; 2017; 42(4):383-389. PubMed ID: 29472817
[TBL] [Abstract][Full Text] [Related]
57. Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism.
Yang F; Lee G; Fan Y
Angiogenesis; 2024 Apr; ():. PubMed ID: 38580870
[TBL] [Abstract][Full Text] [Related]
58. Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?
Escors D; Liechtenstein T; Perez-Janices N; Schwarze J; Dufait I; Goyvaerts C; Lanna A; Arce F; Blanco-Luquin I; Kochan G; Guerrero-Setas D; Breckpot K
Oncoimmunology; 2013 Oct; 2(10):e26148. PubMed ID: 24244902
[TBL] [Abstract][Full Text] [Related]
59. Targeted Therapy of Interleukin-34 as a Promising Approach to Overcome Cancer Therapy Resistance.
Monteleone G; Franzè E; Maresca C; Colella M; Pacifico T; Stolfi C
Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765929
[TBL] [Abstract][Full Text] [Related]
60. Myeloid-derived suppressor cells in gastrointestinal cancers: A systemic review.
Farshidpour M; Ahmed M; Junna S; Merchant JL
World J Gastrointest Oncol; 2021 Jan; 13(1):1-11. PubMed ID: 33510845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
